JP2018537399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537399A5 JP2018537399A5 JP2018510074A JP2018510074A JP2018537399A5 JP 2018537399 A5 JP2018537399 A5 JP 2018537399A5 JP 2018510074 A JP2018510074 A JP 2018510074A JP 2018510074 A JP2018510074 A JP 2018510074A JP 2018537399 A5 JP2018537399 A5 JP 2018537399A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- immunoglobulin
- chain variable
- variable region
- region sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562214605P | 2015-09-04 | 2015-09-04 | |
| US62/214,605 | 2015-09-04 | ||
| PCT/US2016/050213 WO2017041001A2 (en) | 2015-09-04 | 2016-09-02 | Insulin immunoglobulin fusion proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537399A JP2018537399A (ja) | 2018-12-20 |
| JP2018537399A5 true JP2018537399A5 (enExample) | 2019-10-03 |
| JP6951825B2 JP6951825B2 (ja) | 2021-10-20 |
Family
ID=58188627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510074A Active JP6951825B2 (ja) | 2015-09-04 | 2016-09-02 | インスリン免疫グロブリン融合タンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10501546B2 (enExample) |
| EP (1) | EP3344278A4 (enExample) |
| JP (1) | JP6951825B2 (enExample) |
| KR (1) | KR20180039726A (enExample) |
| CN (1) | CN108348581B (enExample) |
| AU (1) | AU2016315889A1 (enExample) |
| CA (1) | CA2996716A1 (enExample) |
| HK (1) | HK1258125A1 (enExample) |
| WO (1) | WO2017041001A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6951825B2 (ja) | 2015-09-04 | 2021-10-20 | ザ スクリプス リサーチ インスティテュート | インスリン免疫グロブリン融合タンパク質 |
| US12325732B2 (en) * | 2018-09-12 | 2025-06-10 | Amphastar Nanjing Pharmaceuticals Inc | Pro-insulin aspart structure and method for preparing insulin aspart |
| WO2020072181A1 (en) * | 2018-10-01 | 2020-04-09 | University Of Houston System | Engineered active single-polypeptide chain insulin analogs |
| WO2020083277A1 (zh) * | 2018-10-22 | 2020-04-30 | 上海一宸医药科技有限公司 | 一种双特异性抗体 |
| TWI844709B (zh) * | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| CN110684082B (zh) * | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| CN111041025B (zh) | 2019-12-17 | 2021-06-18 | 深圳市瑞吉生物科技有限公司 | 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 |
| CN111744019B (zh) | 2020-07-01 | 2023-08-04 | 深圳瑞吉生物科技有限公司 | 基于甘露糖的mRNA靶向递送系统及其应用 |
| MX2023006189A (es) * | 2020-11-27 | 2023-07-04 | D&D Pharmatech Inc | Formulacion oral de conjugado de material biologicamente activo que tiene acoplada un resto de biotina, un resto de acido graso o una combinacion de estos. |
| CA3200366A1 (en) * | 2020-11-27 | 2022-06-02 | D&D Pharmatech Inc. | Biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto |
| WO2025098472A1 (zh) * | 2023-11-08 | 2025-05-15 | 北京拓界生物医药科技有限公司 | 融合蛋白及其医药用途 |
| WO2025210538A1 (en) * | 2024-04-02 | 2025-10-09 | Biohaven Therapeutics Ltd. | Bifunctional degraders |
| CN118834293B (zh) * | 2024-08-06 | 2025-09-19 | 扬州大学 | 一种基于h5n8亚型禽流感病毒na的单克隆抗体及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| US6372716B1 (en) | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US6566329B1 (en) | 1999-06-28 | 2003-05-20 | Novo Nordisk A/S | Freeze-dried preparation of human growth hormone |
| UA93662C2 (uk) | 2000-12-07 | 2011-03-10 | Эли Лилли Энд Компани | Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет |
| AU2004292393C1 (en) * | 2003-11-21 | 2011-08-04 | Ucb Pharma S.A. | Method for the treatment of multiple sclerosis by inhibiting IL-17 activity |
| EA011859B9 (ru) * | 2004-01-05 | 2013-07-30 | Емд Лексиген Ресерч Сентер Корп. | Соединения для адресной доставки препарата к ткани или органу-мишени |
| US7871632B2 (en) | 2004-07-12 | 2011-01-18 | Adventrx Pharmaceuticals, Inc. | Compositions for delivering highly water soluble drugs |
| EP1869084A2 (en) * | 2005-03-04 | 2007-12-26 | Biogen Idec MA Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
| US20110135725A1 (en) * | 2005-05-23 | 2011-06-09 | Sdg, Inc. | Lipid Construct for Delivery of Insulin to a Mammal |
| WO2007064911A1 (en) | 2005-12-02 | 2007-06-07 | Biogen Idec Inc. | Anti-mouse cd20 antibodies and uses thereof |
| ES2554773T3 (es) | 2006-10-04 | 2015-12-23 | Case Western Reserve University | Insulina y análogos de la insulina resistentes a la fibrilación |
| CN101589059A (zh) | 2006-10-20 | 2009-11-25 | 株式会社未来创药研究所 | 包含抗hb-egf抗体作为活性成分的药物组合物 |
| FR2929509B1 (fr) | 2008-04-02 | 2011-01-21 | Lvmh Rech | L'utilisation de glycosides d'alkyle ou de melanges de glycosides d'alkyle en tant qu'agents destines a inhiber la croissance microbienne, et compositions contenant lesdits glycosides d'alkyle. |
| CN102065885A (zh) | 2008-04-22 | 2011-05-18 | 卡斯西部储备大学 | 同种型特异性的胰岛素类似物 |
| EP2166021A1 (en) * | 2008-09-16 | 2010-03-24 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| JP2013516967A (ja) * | 2010-01-14 | 2013-05-16 | グラクソ グループ リミテッド | 肝臓標的化ドメイン抗体 |
| AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| TWI560199B (en) | 2010-08-31 | 2016-12-01 | Sanofi Sa | Peptide or peptide complex binding to α2 integrin and methods and uses involving the same |
| CA2866252A1 (en) * | 2012-03-06 | 2013-09-12 | Order-Made Medical Research Inc. | Pharmaceutical composition for treating cancer |
| WO2013134365A1 (en) * | 2012-03-08 | 2013-09-12 | Ludwig Institute For Cancer Research Ltd | TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF |
| CA2878626A1 (en) * | 2012-08-09 | 2014-02-13 | Roche Glycart Ag | Asgpr antibodies and uses thereof |
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| CA2946064C (en) | 2014-02-21 | 2023-09-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10995148B2 (en) | 2014-03-19 | 2021-05-04 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| JP6951825B2 (ja) | 2015-09-04 | 2021-10-20 | ザ スクリプス リサーチ インスティテュート | インスリン免疫グロブリン融合タンパク質 |
-
2016
- 2016-09-02 JP JP2018510074A patent/JP6951825B2/ja active Active
- 2016-09-02 HK HK19100415.6A patent/HK1258125A1/zh unknown
- 2016-09-02 CA CA2996716A patent/CA2996716A1/en not_active Abandoned
- 2016-09-02 EP EP16843113.8A patent/EP3344278A4/en not_active Withdrawn
- 2016-09-02 US US15/756,296 patent/US10501546B2/en active Active
- 2016-09-02 CN CN201680063883.8A patent/CN108348581B/zh active Active
- 2016-09-02 KR KR1020187008446A patent/KR20180039726A/ko not_active Ceased
- 2016-09-02 WO PCT/US2016/050213 patent/WO2017041001A2/en not_active Ceased
- 2016-09-02 AU AU2016315889A patent/AU2016315889A1/en not_active Abandoned
-
2019
- 2019-10-24 US US16/663,239 patent/US11421033B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537399A5 (enExample) | ||
| JP2018504907A5 (enExample) | ||
| JP2017176174A5 (enExample) | ||
| WO2016126858A3 (en) | Antibodies directed against lymphocyte activation gene 3 (lag-3) | |
| JP2017048194A5 (enExample) | ||
| JP2019524645A5 (enExample) | ||
| JP2013539454A5 (enExample) | ||
| EA201792184A1 (ru) | Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3) | |
| EA201892362A1 (ru) | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения | |
| JP2020513804A5 (enExample) | ||
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| JP2017528117A5 (enExample) | ||
| JOP20220119A1 (ar) | أجسام مضادة trem2 واستخداماتها | |
| MX2019009117A (es) | Anticuerpos anti alfa-sinucleina y usos de los mismos. | |
| JP2014237714A5 (enExample) | ||
| SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| WO2014186622A3 (en) | Methods of treatment for guillain-barre syndrome | |
| WO2016207304A8 (en) | Monoclonal anti-il-1racp antibodies | |
| EA201591153A1 (ru) | Антитела, связывающиеся с tl1a, и их применение | |
| NZ626520A (en) | Anti-lrp5 antibodies and methods of use | |
| JP2016515524A5 (enExample) | ||
| JP2021500874A5 (enExample) | ||
| WO2012162394A3 (en) | Compositions and methods for treating renal disease | |
| JP2015523910A5 (enExample) | ||
| WO2015127140A3 (en) | Marburg monoclonal antibodies |